Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TetraLogic Pharmaceuticals Corporation (TLOG)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
343 Phoenixville Pike 19355
Malvern, PA, US
Malvern, PA, US
CEO
Yigong Shi
Website
tetralogicpharma.com
IPO
2013-12-12
CIK 1361248 ISIN US88165U1097
Description
TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on identifying and advancing small-molecule treatments for cancer and infectious diseases. The company's development pipeline features two key clinical-stage drug candidates: birinapant and SHAPE. Birinapant, a small molecule, functions as a Second Mitochondrial Activator of Caspases (SMAC) mimetic, promoting programmed cell death, or apoptosis, in compromised cells. SHAPE, another proprietary compound, is a histone deacetylase (HDAC) inhibitor intended for topical administration to address early-stage cutaneous T-cell lymphoma. Furthermore, TetraLogic Pharmaceuticals has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to explore the application of SMAC-mimetics, including birinapant, in treating infectious diseases. Founded in 2001 as Gentara Corporation, the company adopted its current name, TetraLogic Pharmaceuticals Corporation, in January 2006 and maintains its headquarters in Malvern, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8
Beta
4.06
Float Shares
21.77M
Free Float %
89.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -60.00% | -60.00% | -60.00% | -60.00% | -60.00% | -60.00% | -99.80% | -99.99% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-10.60
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-34.1% Q3'16: +32.7% (vs Q3'15)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-2,246.6% Q3'16: +482.0% (vs Q3'15)
-
Share dilution Biotechnology: -3.4%+6.2% Q3'16: +3.8% (vs Q3'15)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.66× Q3'16: -0.84× (vs Q3'15)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
38
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Clarus Lifesciences II, L.P. | 4.64M | 22.00% | — | 4.64M | — | 10.00 | PN | Delaware | 2013-12-27 | ↗ |
| 2 | Clarus Ventures II GP, L.P. | 4.64M | 22.00% | — | 4.64M | — | 10.00 | PN | Delaware | 2013-12-27 | ↗ |
| 3 | Clarus Ventures II, LLC | 4.64M | 22.00% | — | 4.64M | — | 10.00 | PN | Delaware | 2013-12-27 | ↗ |
| 4 | Dennis Henner | 4.64M | 22.00% | — | 4.64M | — | 10.00 | IN | United States Citizen | 2013-12-27 | ↗ |
| 5 | Kurt Wheeler | 4.64M | 22.00% | — | 4.64M | — | 10.00 | IN | United States citizen | 2013-12-27 | ↗ |
| 6 | Michael Steinmetz | 4.64M | 22.00% | — | 4.64M | — | 10.00 | IN | German citizen | 2013-12-27 | ↗ |
| 7 | Nicholas Galakatos | 4.64M | 22.00% | — | 4.64M | — | 10.00 | IN | United States citizen | 2013-12-27 | ↗ |
| 8 | Nicholas Simon | 4.64M | 22.00% | — | 4.64M | — | 10.00 | IN | United States citizen | 2013-12-27 | ↗ |
| 9 | Robert Liptak | 4.64M | 22.00% | — | 4.64M | — | 10.00 | IN | United States citizen | 2013-12-27 | ↗ |
| 10 | Augustine Lawlor | 2.62M | 12.40% | — | 2.62M | — | 2.62M | IN | USA | 2013-12-26 | ↗ |
| 11 | Christopher Mirabelli, Ph.D. | 2.62M | 12.40% | — | 2.62M | — | 2.62M | IN | USA | 2013-12-26 | ↗ |
| 12 | Harold R. Werner | 2.62M | 12.40% | — | 2.62M | — | 2.62M | IN | USA | 2013-12-26 | ↗ |
| 13 | HealthCare Partners VII, L.P. | 2.62M | 12.40% | — | 2.62M | — | 2.62M | PN | Delaware | 2013-12-26 | ↗ |
| 14 | HealthCare Ventures VII, L.P. | 2.62M | 12.40% | — | 2.62M | — | 2.62M | PN | Delaware | 2013-12-26 | ↗ |
| 15 | James H. Cavanaugh, Ph.D. | 2.62M | 12.40% | — | 2.62M | — | 2.62M | IN | USA | 2013-12-26 | ↗ |
| 16 | John W. Littlechild | 2.62M | 12.40% | — | 2.62M | — | 2.62M | IN | USA | 2013-12-26 | ↗ |
| 17 | Michael Bolton | 1.54M | 11.00% | — | 1.54M | — | 1.54M | IN | USA | 2013-12-27 | ↗ |
| 18 | Novitas Capital III GP Manager, LLC | 1.54M | 11.00% | — | 1.54M | — | 1.54M | CO | Delaware | 2013-12-27 | ↗ |
| 19 | Novitas Capital III GP, LP | 1.54M | 11.00% | — | 1.54M | — | 1.54M | PN | Delaware | 2013-12-27 | ↗ |
| 20 | Novitas Capital III, LP | 1.54M | 11.00% | — | 1.54M | — | 1.54M | PN | Delaware | 2013-12-27 | ↗ |
| 21 | Paul Schmitt | 1.54M | 11.00% | — | 1.54M | — | 1.54M | IN | USA | 2013-12-27 | ↗ |
| 22 | Stephen Barnes | 1.54M | 11.00% | — | 1.54M | — | 1.54M | IN | USA | 2013-12-27 | ↗ |
| 23 | David C. Robins | 1.45M | 5.85% | 1.45M | — | 1.45M | — | IN | USA | 2017-08-04 | ↗ |
| 24 | Clay B. Thorp | 1.21M | 5.70% | — | 1.21M | — | — | IN | USA | 2013-12-27 | ↗ |
| 25 | Douglas Reed | 1.21M | 5.70% | — | 1.21M | — | — | IN | USA | 2013-12-27 | ↗ |
| 26 | Hatteras Venture Advisors III, LLC | 1.21M | 5.70% | — | 1.21M | — | — | CO | USA | 2013-12-27 | ↗ |
| 27 | Hatteras Venture Affiliates III, L.P. | 1.21M | 5.70% | — | 1.21M | — | — | PN | USA | 2013-12-27 | ↗ |
| 28 | Hatteras Venture Partners III, L.P. | 1.21M | 5.70% | — | 1.21M | — | — | PN | USA | 2013-12-27 | ↗ |
| 29 | John C. Crumpler | 1.21M | 5.70% | — | 1.21M | — | — | IN | USA | 2013-12-27 | ↗ |
| 30 | Kenneth B. Lee | 1.21M | 5.70% | — | 1.21M | — | — | IN | USA | 2013-12-27 | ↗ |
| 31 | Robert A. Ingram | 1.21M | 5.70% | — | 1.21M | — | — | IN | USA | 2013-12-27 | ↗ |
| 32 | Alfred Scheidegger | 1.13M | 6.09% | — | 1.13M | — | — | IN | Switzerland | 2013-12-27 | ↗ |
| 33 | Nextech III GP Ltd. | 1.13M | 6.09% | 1.13M | — | 1.13M | — | OO | Switzerland | 2013-12-27 | ↗ |
| 34 | Nextech III Oncology, LPCI | 1.13M | 6.09% | 1.13M | — | 1.13M | — | PN | Switzerland | 2013-12-27 | ↗ |
| 35 | Roland Ruckstuhl | 1.13M | 6.09% | — | 1.13M | — | — | IN | Switzerland | 2013-12-27 | ↗ |
| 36 | Rudolf Gygax | 1.13M | 6.09% | — | 1.13M | — | — | IN | Switzerland | 2013-12-27 | ↗ |
| 37 | Highbridge Capital Management, LLC | — | 0.00% | — | — | — | 10.00 | OO | Delaware | 2016-11-14 | ↗ |
| 38 | Lazard Asset Management LLC | — | 0.00% | — | — | — | 10.00 | IA | Delaware | 2016-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-11-14 | WHITEBOX ADVISORS LLC | Other | J-Other | A | Preferred Stock | 3,018,260 | 0.00 | — | 3,018,260 | — | ↗ |
| 2016-11-14 | Hudson Bay Capital Management LP | Other | J-Other | A | Preferred Stock | 279,367 | 0.00 | — | 279,367 | — | ↗ |
| 2016-11-14 | HIGHBRIDGE CAPITAL MANAGEMENT LLC | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-11-02 | WHITEBOX ADVISORS LLC | Other | — | I | 8% Senior Convertible Notes due 2019 | 1,602,253 | 0.00 | — | 0 | — | ↗ |
| 2016-11-02 | Hudson Bay Capital Management LP | Other | — | I | 8% Senior Convertible Notes due 2019 | 148,301 | 0.00 | — | 0 | — | ↗ |
| 2016-11-02 | HIGHBRIDGE CAPITAL MANAGEMENT LLC | Other | — | I | 8% Senior Convertible Notes due 2019 (the "Senior Notes") | 778,584 | 0.00 | — | 0 | — | ↗ |
| 2016-04-30 | Hutchison Patrick | Officer | — | D | Stock Option (Right to Purchase) | 25,000 | 7.72 | 193.0K | 0 | — | ↗ |
| 2016-02-09 | Clarus Lifesciences II, L.P. | 10% Owner | S-Sale | D | Common Stock | 230,507 | 0.16 | 36.9K | 2,214,523 | — | ↗ |
| 2016-02-08 | Clarus Lifesciences II, L.P. | 10% Owner | S-Sale | D | Common Stock | 103,123 | 0.19 | 19.6K | 2,445,030 | — | ↗ |
| 2016-02-05 | Clarus Lifesciences II, L.P. | 10% Owner | S-Sale | D | Common Stock | 832,881 | 0.20 | 166.6K | 2,548,153 | — | ↗ |
| 2016-02-04 | Clarus Lifesciences II, L.P. | 10% Owner | S-Sale | D | Common Stock | 500,026 | 0.14 | 70.0K | 3,381,034 | — | ↗ |
| 2016-02-03 | Clarus Lifesciences II, L.P. | 10% Owner | S-Sale | D | Common Stock | 82,583 | 0.15 | 12.4K | 3,881,060 | — | ↗ |
| 2016-02-02 | Clarus Lifesciences II, L.P. | 10% Owner | S-Sale | D | Common Stock | 176,306 | 0.17 | 30.0K | 3,963,643 | — | ↗ |
| 2016-02-01 | Clarus Lifesciences II, L.P. | 10% Owner | S-Sale | D | Common Stock | 140,000 | 0.20 | 28.0K | 4,139,949 | — | ↗ |
| 2016-01-29 | Clarus Lifesciences II, L.P. | 10% Owner | S-Sale | D | Common Stock | 52,826 | 0.26 | 13.7K | 4,279,949 | — | ↗ |
| 2016-01-28 | Clarus Lifesciences II, L.P. | 10% Owner | S-Sale | D | Common Stock | 32,521 | 0.26 | 8.5K | 4,332,775 | — | ↗ |
| 2016-01-27 | Clarus Lifesciences II, L.P. | 10% Owner | S-Sale | D | Common Stock | 209,984 | 0.27 | 56.7K | 4,365,296 | — | ↗ |
| 2016-01-26 | Clarus Lifesciences II, L.P. | 10% Owner | S-Sale | D | Common Stock | 69,425 | 0.30 | 20.8K | 4,575,280 | — | ↗ |
| 2015-07-10 | Pecora Andrew L | Director | P-Purchase | A | Common Stock | 1,300 | 2.54 | 3.3K | 146,130 | — | ↗ |
| 2015-07-09 | Pecora Andrew L | Director | P-Purchase | A | Common Stock | 10,000 | 2.41 | 24.1K | 134,830 | — | ↗ |
| 2015-03-27 | Meyers Pete A. | Officer | P-Purchase | A | Common Stock | 5,000 | 4.35 | 21.8K | 153,891 | — | ↗ |
| 2015-03-26 | BUCHI J KEVIN | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 4.23 | 21.1K | 330,714 | — | ↗ |
| 2015-01-28 | Woody James N. | Director | A-Award | A | Stock Option | 10,000 | 5.25 | 52.5K | 30,000 | — | ↗ |
| 2015-01-28 | STEINMETZ MICHAEL | Director | A-Award | A | Stock Option | 10,000 | 5.25 | 52.5K | 30,000 | — | ↗ |
| 2015-01-28 | Reed Douglas MD | Director | A-Award | A | Stock Option | 10,000 | 5.25 | 52.5K | 30,000 | — | ↗ |
| 2015-01-28 | Pecora Andrew L | Director | A-Award | A | Stock Option | 10,000 | 5.25 | 52.5K | 77,644 | — | ↗ |
| 2015-01-28 | ONSI DOUGLAS E | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 5.25 | 52.5K | 10,000 | — | ↗ |
| 2015-01-28 | Meyers Pete A. | Officer | A-Award | A | Restricted Stock Unit | 75,000 | 0.00 | — | 0 | — | ↗ |
| 2015-01-28 | KISHBAUCH MICHAEL D | Director | A-Award | A | Stock Option | 10,000 | 5.25 | 52.5K | 30,000 | — | ↗ |
| 2015-01-28 | GRAY MARY ANN | Director | A-Award | A | Stock Option | 10,000 | 5.25 | 52.5K | 30,000 | — | ↗ |
| 2015-01-28 | BUCHI J KEVIN | Director / Officer | A-Award | A | Stock Option | 200,000 | 5.25 | 1.05M | 1,222,389 | — | ↗ |
| 2015-01-07 | BUCHI J KEVIN | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 5.04 | 25.2K | 325,714 | — | ↗ |
| 2014-12-09 | BUCHI J KEVIN | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 6.01 | 30.1K | 320,714 | — | ↗ |
| 2014-12-04 | Meyers Pete A. | Officer | P-Purchase | A | Common Stock | 1,034 | 4.94 | 5.1K | 148,891 | — | ↗ |
| 2014-12-02 | BUCHI J KEVIN | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.99 | 49.9K | 315,714 | — | ↗ |
| 2014-11-18 | BUCHI J KEVIN | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.82 | 48.2K | 305,714 | — | ↗ |
| 2014-11-17 | Pecora Andrew L | Director | P-Purchase | A | Common Stock | 20,000 | 4.53 | 90.6K | 84,830 | — | ↗ |
| 2014-11-12 | Meyers Peter A. | Officer | P-Purchase | A | Common Stock | 5,000 | 3.98 | 19.9K | 147,857 | — | ↗ |
| 2014-11-11 | BUCHI J KEVIN | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 3.93 | 39.3K | 295,714 | — | ↗ |
| 2014-11-05 | KISHBAUCH MICHAEL D | Director | A-Award | A | Stock Options (right to buy) | 20,000 | 3.87 | 77.4K | 20,000 | — | ↗ |
| 2014-11-05 | GRAY MARY ANN | Director | A-Award | A | Stock Options (right to buy) | 20,000 | 3.87 | 77.4K | 20,000 | — | ↗ |
| 2013-12-31 | Woody James N. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-12-31 | STEINMETZ MICHAEL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-12-31 | Reed Douglas MD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-12-31 | Pecora Andrew L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-12-31 | GILL JOHN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-12-30 | Meyers Peter A. | Director | A-Award | A | Stock options | 23,307 | 10.00 | 233.1K | 511,195 | — | ↗ |
| 2013-12-30 | BUCHI J KEVIN | Director / Officer | A-Award | A | Stock Option | 46,614 | 10.00 | 466.1K | 1,022,389 | — | ↗ |
| 2013-12-17 | Woody James N. | Director | C-Conversion | A | Common Stock | 5,681 | 0.00 | — | 886,999 | — | ↗ |
| 2013-12-17 | Reed Douglas MD | Director | P-Purchase | A | Common Stock | 142,857 | 7.00 | 1,000.0K | 142,857 | — | ↗ |
| 2013-12-17 | Pecora Andrew L | Director | P-Purchase | A | Common Stock | 26,551 | 7.00 | 185.9K | 42,727 | — | ↗ |
| 2013-12-17 | Meyers Peter A. | Officer | P-Purchase | A | Common Stock | 142,857 | 7.00 | 1,000.0K | 142,857 | — | ↗ |
| 2013-12-17 | HEALTHCARE VENTURES VII LP | 10% Owner | C-Conversion | A | Common Stock | 506,086 | 0.00 | — | 1,598,133 | — | ↗ |
| 2013-12-17 | Clarus Lifesciences II, L.P. | 10% Owner | C-Conversion | D | Series C Convertible Preferred Stock | 2,342,944 | 0.00 | — | 0 | — | ↗ |
| 2013-12-17 | BUCHI J KEVIN | Director / Officer | A-Award | A | Stock Option | 167,040 | 7.00 | 1.17M | 975,775 | — | ↗ |
| 2013-12-17 | AMGEN INC | 10% Owner | C-Conversion | D | Series B Convertible Preferred Stock | 108,932 | 0.00 | — | 0 | — | ↗ |
| 2013-12-11 | Woody James N. | Director | — | I | Series C Convertible Preferred Stock | 5,681 | 0.00 | — | 0 | — | ↗ |
| 2013-12-11 | Reed Douglas MD | Director | — | I | Series C Convertible Preferred Stock | 780,980 | 0.00 | — | 0 | — | ↗ |
| 2013-12-11 | Pecora Andrew L | Director | — | I | Convertible Notes | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-12-11 | ONSI DOUGLAS E | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 7.00 | 140.0K | 20,000 | — | ↗ |
| 2013-12-11 | Meyers Peter A. | Officer | — | D | Stock Option (right to purchase) | 323,494 | 6.12 | 1.98M | 0 | — | ↗ |
| 2013-12-11 | HEALTHCARE VENTURES VII LP | 10% Owner | — | I | Notes | 266,572 | 0.00 | — | 0 | — | ↗ |
| 2013-12-11 | GILL JOHN | Director | — | D | Common Stock | 0 | 0.00 | — | 40,312 | — | ↗ |
| 2013-12-11 | Clarus Lifesciences II, L.P. | 10% Owner | — | D | Series C Convertible Preferred Stock | 2,342,944 | 0.00 | — | 0 | — | ↗ |
| 2013-12-11 | BUCHI J KEVIN | Director / Officer | — | D | Stock Option (right to purchase) | 808,735 | 6.12 | 4.95M | 0 | — | ↗ |
| 2013-12-11 | AMGEN INC | 10% Owner | — | I | Convertible Notes | 0 | 7.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
24.47M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yigong Shi | Co-Founder | — | — |
ESG Rating
ESG Score History
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TLOG
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
